title: Reintroduction of Anti-TNFα Therapy After (or even During) Anti-TNFα-associated Tuberculosis in Immune-mediated Diseases.
authors.affiliation: Department of Infectious Diseases, Faculty of Medicine, Centro Hospitalar S. João, Porto, Portugal Instituto de Inovação e Investigação em Saúde (I3S), Grupo de I&D em Nefrologia e Doenças Infecciosas, Instituto Nacional de Engenharia Biomédica (INEB), Porto, Portugal.
authors.forename: C
authors.initials: C
authors.lastname: Abreu
authors.affiliation: Department of Infectious Diseases, Faculty of Medicine, Centro Hospitalar S. João, Porto, Portugal Instituto de Inovação e Investigação em Saúde (I3S), Grupo de I&D em Nefrologia e Doenças Infecciosas, Instituto Nacional de Engenharia Biomédica (INEB), Porto, Portugal.
authors.forename: A
authors.initials: A
authors.lastname: Sarmento
authors.affiliation: Department of Gastroenterology, Faculty of Medicine, Centro Hospitalar S. João, Porto, Portugal Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto, Portugal MedInUP - Center for Drug Discovery and Innovative Medicines, University of Porto, Porto, Portugal fm@med.up.pt.
authors.forename: F
authors.initials: F
authors.lastname: Magro
mesh_terms: D000328:Adult; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D015331:Cohort Studies; D015897:Comorbidity; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016867:Immunocompromised Host; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000453:epidemiology* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D061214:Patient Safety; D011446:Prospective Studies; D012008:Recurrence; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014376:Tuberculosis / Q000188:drug therapy* / Q000453:epidemiology* / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage / Q000037:antagonists & inhibitors*; D055815:Young Adult
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha